The profit warning is broadly in line with expectations, with the key focus on continued delivery from the AI4S platform
AI summary card
The profit warning is broadly in line with expectations, with the key focus on continued delivery from the AI4S platform
JPMorgan maintains its Overweight rating and HK$10.00 target price on XtalPi - H, believing that the short-term loss is mainly due to DoveTree's high base and R&D investment, while non-BD business and AI for Science remain the core drivers of medium-term growth.
- 1H26 revenue guidance is RMB380-400mn, below RMB517.1mn in 1H25, mainly because the recognition of the US$51mn upfront payment from the DoveTree project in 1H25 created a high base.
- Excluding DoveTree revenue, management guides 1H26 non-BD revenue to be no less than RMB250mn, with YoY growth of more than 65%; among this, AI for Science revenue is expected to be no less than RMB180mn, with YoY growth of more than 120%.
- 1H26 R&D expenses are expected to be no less than RMB340mn, up more than 50% YoY, suppressing short-term profit but supporting the medium-term commercialization of autonomous laboratories, agentic systems, multimodal platforms, and pipeline assets.
- AI4S Demo Day will be held in Shanghai on July 29, which may help investors more intuitively see the company's progress in iterating its AI platform and tools.
Report interpretation
Overview
This report is JPMorgan's company earnings review on XtalPi - H (2228.HK). The report believes that the company's 1H26 profit warning is broadly in line with expectations, and that the decline in headline revenue and the widening loss are mainly due to the high base created by the US$51mn upfront payment from the DoveTree project in 1H25, as well as the company's continued increase in R&D investment in AI4S, automated laboratories, agentic AI, and multimodal technology platforms.
Core views
The core view is that short-term profit pressure does not mean deterioration in business quality. Excluding DoveTree-related BD revenue, the company's non-BD service revenue and AI for Science business still maintained strong growth, demonstrating that its service-driven AI drug discovery and scientific intelligence platform has sustainable commercialization capabilities. JPMorgan believes that compared with pipeline-based companies that rely on single clinical binary events, XtalPi has earlier and more diversified revenue sources, and has formed a differentiated moat through its robot-driven Physical AI closed-loop experimental platform.
Analysis framework
The report uses a combination of profit warning breakdown, base adjustment, segment growth analysis, and valuation framework: it first explains the high-base reason for the YoY decline in 1H26 revenue, then excludes DoveTree revenue to observe momentum in the non-BD business, then assesses the impact of rising R&D expenses on short-term profit and medium-term platform capabilities, and finally supports the Dec-2027 target price with SOTP valuation.
Methodology notes
sum-of-the-parts valuation
JPMorgan breaks XtalPi's business into three parts: intelligent solutions, drug discovery, and self-developed pipeline. The first two are valued using AI-enabled EV/S, and the third is valued using risk-adjusted net present value, or rNPV.
risk-adjusted net present value
The self-developed pipeline is risk-adjusted based on probability of success and future cash flows to reflect the uncertainty of drug development assets.
underlying growth analysis excluding high-base items
The report separately excludes the high base created by the DoveTree upfront payment in 1H25 in order to observe the true growth momentum of non-BD revenue and the AI for Science business.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- 2228.HKCovered stock in the report; JPMorgan maintains Overweight rating
- Strengths
- Rapid growth in AI for Science revenue; strong momentum in non-BD revenue; differentiated robot-driven Physical AI platform; blue-chip partners including Eli Lilly, Janssen, UCB, and Pfizer; business does not rely entirely on a single clinical binary event.
- Weaknesses
- Revenue is still affected by the timing of milestones and BD projects, while short-term profit is pressured by high R&D investment.
- Comparison
- The report believes that compared with pipeline-centric AI drug discovery peers, XtalPi has a commercialization path that is earlier-stage, more service-driven, and less dependent on binary events; its implied 2027E P/S is about 25x, below the roughly 60x median for global AIDD peers.
- Risks
- Weaker sentiment around the AI theme, slow progress in out-licensing deals or deal value below expectations, unfavorable clinical trial results, geopolitical and China-US relations risks, and sales and profitability coming in below expectations.
Key data
- 1H26 revenue guidanceRMB380-400mnManagement profit warning guidance, below RMB517.1mn in 1H25.
- 1H26 net profit expectationloss of RMB215-275mnExpected to turn from profit to loss, mainly affected by the high base and R&D investment.
- 1H25 DoveTree upfront paymentUS$51mn / RMB365.1mnRevenue recognized in 1H25, resulting in a high YoY comparison base.
- 1H26 DoveTree second paymentUS$19mn / RMB129.4mnRecognized in 1H26 as revenue from drug discovery work.
- 1H26 non-BD revenueno less than RMB250mn; YoY growth of more than 65%Reflects underlying operating momentum after excluding DoveTree revenue.
- 1H26 AI for Science revenueno less than RMB180mn; YoY growth of more than 120%Supported by new customer expansion, repeat orders from existing customers, technology iteration, and delivery quality.
- 1H26 R&D expensesno less than RMB340mn; YoY growth of more than 50%Investment areas include autonomous laboratories, agentic systems, pipeline development, and multimodal technology platforms.
- Current share priceHK$7.20Price as of July 24, 2026.
- Target priceHK$10.00Dec-2027 target price, based on SOTP valuation.
- Implied 2027E P/Sabout 25xAt the low end of the 5x-173x range for global AIDD peers; peer median is about 60x.
Impact & implications
The report's investment implication is positive overall: although the profit warning highlights short-term loss pressure, JPMorgan believes this is more the result of a high base and proactive R&D investment rather than a deterioration in the company's competitiveness. If AI4S Demo Day, customer expansion, partner milestones, asset advancement, and new BD opportunities continue to deliver, the market may refocus on platform commercialization and medium-term revenue growth potential.
Risks
- Deterioration in sentiment toward the AI theme and the AI drug discovery market.
- Slow progress in out-licensing deals or deal value below expectations.
- Unfavorable clinical trial results.
- Rising geopolitical risks such as China-US relations.
- Sales and profitability performance below expectations.
- Revenue has milestone-driven characteristics and may experience periodic volatility.
- Sustained high R&D investment may continue to suppress short-term profitability.
What to watch
- The AI platform, tools, and technology iteration achievements presented at the Shanghai AI4S Demo Day on July 29, 2026.
- Whether non-BD service revenue can maintain high growth.
- New customer expansion and repeat purchases from existing customers in AI for Science.
- Follow-up payments and progress in drug discovery work for the DoveTree collaboration project.
- Commercialization conversion of autonomous laboratories, agentic systems, multimodal platforms, and self-developed pipelines.
- Partner milestones, asset advancement, and new business development opportunities.